Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.73 |
| ▸ | HTR2A | P28223 | 2/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | IDO1 | P14902 | 1/20 | 0.52 |
| ▸ | HRH1 | P35367 | 4/20 | 0.50 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.50 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9556361 | 0.98 | MAOA (0.70) | MAOAHTR2ATDP1L3MBTL1IDO1 | |
| SCHEMBL22268839 | 0.96 | MAOA (0.67) | MAOAHTR2ATDP1L3MBTL1IDO1 | |
| SCHEMBL10818930 | 0.94 | MAOA (0.69) | MAOAHTR2AIDO1CYP2A6SMN1; SMN2 | |
| SCHEMBL1579959 | 0.92 | MAOA (0.61) | MAOAHTR2ATDP1L3MBTL1IDO1 | |
| SCHEMBL29263651 | 0.90 | MAOA (0.63) | MAOAHTR2ATDP1L3MBTL1IDO1 | |
| SCHEMBL19472539 | 0.90 | MAOA (0.63) | MAOAHTR2AIDO1CYP2A6SMN1; SMN2 | |
| SCHEMBL7448881 | 0.90 | TDP1 (0.61) | MAOATDP1L3MBTL1IDO1SIGMAR1 | |
| SCHEMBL7449055 | 0.90 | TDP1 (0.61) | MAOATDP1L3MBTL1IDO1SIGMAR1 | |
| SCHEMBL7449325 | 0.90 | TDP1 (0.61) | MAOATDP1L3MBTL1IDO1SIGMAR1 | |
| SCHEMBL8048487 | 0.90 | TDP1 (0.61) | MAOATDP1L3MBTL1IDO1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101712622-B | Method for preparing anti-asthmatic medicament of salmeterol | UNIV ZHEJIANG WANLI | 2012-10-03 | — | — | CN | claimed |
| CN-101712622-A | Method for preparing anti-asthmatic medicament of salmeterol | UNIV ZHEJIANG WANLI | 2010-05-26 | — | — | CN | claimed |
| EP-1132373-B1 | NEW DERIVATIVES OF 6-(4-PHENYLBUTOXY)HEXYLAMINE AND PROCESS FOR PRODUCING SALMETEROL | VITA LAB (ES) | 2003-11-19 | — | — | EP | claimed |
| US-6388134-B1 | CHEMICAL INTERMEDIATES | INKE, S.A. (ES) | 2002-05-14 | — | — | US | claimed |
| EP-1132373-A2 | NEW DERIVATIVES OF 6-(4-PHENYLBUTOXY)HEXYLAMINE AND PROCESS FOR PRODUCING SALMETEROL | VITA-INVEST, S.A. (ES) | 2001-09-12 | — | — | EP | claimed |
| US-20250319096-A1 | METHODS AND COMPOUNDS FOR TREATING INFLAMMATION | PANTHERICS INCORPERATED (US) | 2025-10-16 | — | — | US | disclosed |
| EP-3570814-B1 | MOLECULAR ADJUVANTS FOR ENHANCED CYTOSOLIC DELIVERY OF ACTIVE AGENTS | UNIV GENT (BE) | 2023-11-29 | — | — | EP | disclosed |
| WO-2023059443-A1 | METHODS AND COMPOUNDS FOR TREATING INFLAMMATION | PANTHERICS INCORPORATED (US) | 2023-04-13 | — | — | WO | disclosed |
| CN-105884625-A | synthetic method of R-salmeterol | 浙江工业大学 | 2016-08-24 | — | — | CN | disclosed |
| EP-1937626-B1 | Process and intermediates for the preparation of Salmeterol | GENERICS UK LTD (GB) | 2016-02-17 | — | — | EP | disclosed |
| US-8648214-B2 | Processes suitable for the preparation of salmeterol | GENERICS [UK] LIMITED (GB) | 2014-02-11 | — | — | US | disclosed |
| US-8648214-B2 | Processes suitable for the preparation of salmeterol | GENERICS [UK] LIMITED (GB) | 2014-02-11 | — | — | US | disclosed |
| US-5243076-A | Adrenergic stimulant intermediates | GLAXO GROUP LTD. | 1993-09-07 | — | — | US | disclosed |
| US-5236900-A | Treating Candida infections | SCHERING CORPORATION (US) | 1993-08-17 | — | — | US | disclosed |
| US-5225445-A | Respiratory system disorders | GLAXO GROUP LTD. | 1993-07-06 | — | — | US | disclosed |
| EP-0500853-A1 | PHENYLETHANOLAMINES, DRUGS CONTAINING THESE COMPOUNDS, AND A METHOD OF PREPARING THEM. | THOMAE GMBH DR K (DE) | 1992-09-02 | — | — | EP | disclosed |
| US-5126375-A | Asthma, chronic bronchitis | GLAXO GROUP LTD. (GB) | 1992-06-30 | — | — | US | disclosed |
| WO-1992004316-A1 | PHENYLETHANOLAMINES, DRUGS CONTAINING THESE COMPOUNDS, AND A METHOD OF PREPARING THEM | DR. KARL THOMAE GMBH (DE) | 1992-03-19 | — | — | WO | disclosed |
| US-5091422-A | Treating inflammatory or allergic skin disease, lowering gastric acidity | GLAXO GROUP LIMITED (GB) | 1992-02-25 | — | — | US | disclosed |
| US-4992474-A | Adrenergic stimulants | GLAXO GROUP LTD. (GB) | 1991-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250319096-A1 | METHODS AND COMPOUNDS FOR TREATING INFLAMMATION | MMP8, TNF, MPO | MAOA 1728/4885HTR2A 3458/4885TDP1 3110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.